Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combe co-founder dies

This article was originally published in The Tan Sheet

Executive Summary

Mary Elizabeth Deming Combe, who co-founded Combe Inc. with her husband Ivan Combe, died Sept. 20 in Greenwich, Conn., at age 94. The privately held White Plains, N.Y.-based firm makes skin care brand Lanacane, Cepacol lozenges and Vagisil feminine itch care products. Ivan Combe, who died in January 2000, served 35 years on the board of the Consumer Healthcare Products Association through several of the trade group's incarnations (1"The Tan Sheet" Jan. 17, 2000). The couple's son Chris Combe is chairman and CEO of the company, and Chris Combe's daughter Keech Combe Shetty is global director of Combe Inc.'s feminine care category

You may also be interested in...



OTC, Toiletry Industries Leader Combe Dies At Age 88

CHPA 35-year board member Ivan Combe died Jan. 11 following a stroke. With his death, the OTC drug and toiletry industries have lost a leader who represented the dwindling number of privately owned companies still run by their founder.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel